Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Indo Us Bio-Tech Ltd - 541304 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is informed you that the Board of Directors of the Company has appointed the following Directors on the Board of the Company by passing resolution on 05.08.2021 pursuant to the provisions of the Companies Act, 2013 and SEBI (Listing Obligations & Disclosure Requirements) Regulations;2015: - Appointment of Mrs. Neha Patel (DIN: 09263180) as an Additional Director (Non-Executive Independent) Appointment of Mrs. Shilpa Thumar (DIN: 09259942) as an Additional Director* (Non-Executive Independent)
05-08-2021
Bigul

Indo Us Bio-Tech Ltd - 541304 - Shareholding for the Period Ended June 30, 2021

 Indo Us Bio-Tech Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here
14-07-2021
Bigul

Indo Us Bio-Tech Ltd - 541304 - Statement Of Investor Complaints For The Quarter Ended June 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Dimpy JoshiDesignation :- Company Secretary and Compliance Officer
13-07-2021
Bigul

Indo Us Bio-Tech Ltd - 541304 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 We herewith enclose a Certificate dated 5th July, 2021 under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2021 received from M/s. Bigshare Services Private Limited, Registrar and Share Transfer Agent of our company. Thanking you
07-07-2021
Bigul

Indo Us Bio-Tech Ltd - 541304 - Non-Applicability Of Regulation 23(9) Of SEBI (LODR) Regulations, 2015

 It may please note that as per Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the compliance with the Corporate Governance Provisions as specified in regulations 17, 17A, 18, 19, 20, 21, 22, 23, 24, 24A, 25, 26, 27 and clauses (b) to (i) of sub-regulation (2) of regulation 46 and para-C, D and E of Schedule V shall not apply, in respect of - 1. The Listed Entity, having paid up equity share capital not exceeding rupees Ten Crores and Net worth not exceeding rupees Twenty-Five Crore, as on the last day of the Previous financial year; 2. The Listed Entity which has listed its specified securities on the SME Exchange. Since our Company does not have paid up equity and Net Worth of minimum level as per above referred regulation and it is listed under BSE SME Platform Therefore, our Company is not required to submit Related Party Transactions disclosure as required under Regulation 23(9) of the SEBI (LODR) Regulations, 2015. Thanking You.
02-07-2021
Bigul

Indo Us Bio-Tech Ltd - 541304 - Outcome Of The Meeting Of The Board Of Directors Of The Company Held On 30Th June, 2021 And Submission Of Audited Financial Results Of The Company For The Quarter And Year Ended On 31St March, 2021.

 With reference to above, we hereby inform that meeting of Board of Directors of the Company was held today (i.e., 30/06/2021), in which Board has approved and adopted the standalone and Consolidated Audited Financial Results of the Company for the Quarter and year ended 31st March, 2021.
30-06-2021
Bigul

Indo Us Bio-Tech Ltd - 541304 - Results- Financial Results For March, 31 2021

 With reference to above, we hereby inform that meeting of Board of Directors of the Company was held today (i.e., 30/06/2021), in which Board has approved and adopted the standalone and Consolidated Audited Financial Results of the Company for the Quarter and year ended 31st March, 2021. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose the following: 1. Standalone and Consolidated Audited Financial Results of the Company for quarter and year ended on 31st March, 2021. 2. Auditors'' Report on Standalone and Consolidated Audited Financial Results. Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company have issued their audit reports with unmodified opinion for the Quarter and financial year ended on March 31, 2021.
30-06-2021
Bigul

Indo Us Bio-Tech Ltd - 541304 - Board Meeting Intimation for Considering And Approve Standalone And Consolidated Audited Financial Results Of The Company For The Year Ended March 31, 2021

 Indo Us Bio-Tech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/06/2021 ,inter alia, to consider and approve Standalone and Consolidated Audited Financial Results of the Company for the year ended March 31, 2021 and other incidental matters also. Further, in view of outbreak of COVID-19 pandemic and various Notifications issued by the Ministry of Corporate Affairs / Securities and Exchange Board of India (SEBI), in terms of circular SEBI/HO/CFD/CMD1/P/CIR/2021/556 dated April 29, 2021, the Audited Financial Results can be submitted up to June 30, 2021. Accordingly, the Company intends to avail the said extensions/relaxations. Kindly take the same on your record. Thanking you,
23-06-2021
Bigul

Indo Us Bio-Tech Ltd - 541304 - Compliances- Submission Of Certificate Under Regulation 40(9) And 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year/Year Ended On 31St March, 2021.

 Dear Sir, We are submitting herewith the certificate under Regulation 40(9) & 40(10) of the SEBI (LODR) Regulation 2015 obtained from Practicing Company Secretary for the half year/Year ended on 31st March, 2021. Kindly take the same on your record. Thanking you
08-04-2021
Bigul

Indo Us Bio-Tech Ltd - 541304 - Confirmation Regarding Not Falling Under Large Corporate Criteria With Reference To SEBI Circular No. SEB/HO/DDHS/CIR/P/2018/144 Dated November 26, 2018 And BSE Circular Dated April 11, 2019.

 Pursuant to SEBI Circular No: SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018 with regard to fund raising by issuance of debt securities by large entities and BSE Circular No. LIST/COMP/05/2019-20 dated April 11, 2019, we would like to confirm that the Company does not fulfil the criteria specified in Para 2.2 of the above-mentioned SEBI Circular and hence does not fall in the category of 'Large Corporate' and cannot be considered as a Large Corporate defined under the said circular. Kindly take the same on your record.
08-04-2021
Next Page
Close

Let's Open Free Demat Account